Related Experiment Video

Updated: Jun 4, 2026

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

Abatacept in the treatment of polyarticular JIA: development, clinical utility, and place in therapy

Ofra Goldzweig1, Philip J Hashkes

  • 1Rainbow Babies and Children's Hospital, Cleveland, OH, USA.

Drug Design, Development and Therapy
|February 23, 2011
PubMed

Insights

Abatacept effectively treats polyarticular juvenile idiopathic arthritis (JIA) in children, including those unresponsive to TNF-α blockade. This targeted therapy reduces disease flares and improves quality of life in JIA patients.

Area of Science:

  • Immunology
  • Pediatric Rheumatology
  • Pharmacology

Background:

  • Juvenile idiopathic arthritis (JIA) encompasses chronic arthritides in children, with the polyarthritis subtype posing significant morbidity and treatment challenges.
  • Current treatments combining methotrexate and TNF-α blockade offer inadequate responses for a substantial JIA patient group.
  • Novel therapeutic agents targeting distinct pathogenic pathways are essential for managing aggressive JIA.

Purpose of the Study:

  • To evaluate the efficacy and safety of abatacept in children diagnosed with polyarticular juvenile idiopathic arthritis (JIA).
  • To assess abatacept's effectiveness in patients who have previously failed TNF-α blockade therapy.
  • To determine abatacept's long-term impact on disease activity and health-related quality of life in pediatric JIA.

Main Methods:

  • A randomized, multinational, blinded withdrawal study was conducted in pediatric patients with polyarticular JIA.
  • Patients received abatacept, followed by a withdrawal phase comparing abatacept to placebo.
  • A subsequent three-year open-label extension study assessed long-term outcomes and safety.

Main Results:

  • Abatacept demonstrated efficacy in approximately 70% of JIA patients, including 39% who had not responded to TNF-α blockade.
  • Significantly fewer disease flares were observed in patients continuing abatacept compared to placebo during the withdrawal phase.
  • The open-label extension confirmed sustained efficacy and a positive impact on health-related quality of life.

Conclusions:

  • Abatacept is an effective treatment option for children with polyarticular JIA, particularly for those refractory to existing therapies.
  • The drug exhibits a favorable safety profile and improves quality of life in pediatric patients with JIA.
  • Regulatory approvals in the US and Europe support abatacept's use in specific JIA populations, often in combination therapy.

Keywords:
abataceptjuvenile idiopathic arthritistreatment

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Autoimmune Disorders01:29

Autoimmune Disorders

Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune system...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...